OICR (Dr. R. Al-Awar)

oicr.on.ca
Innovation Type:
Therapeutics
Cancer Type:
Multiple
Funding Stage:
Proof of Concept
Fund:
Prospects
Fully synthetic, self-adjuvanting vaccines based on proprietary synthetic peptidoglycans linked with tumor-associated antigenic epitopes for cancer immunotherapy.

Related news

    CONNECT WITH FACIT

    Learn more about how we are driving made-in-Ontario oncology innovations reach the market.